Picard Faces Lawsuits Alleging Stock Fraud from Sept-Oct 2025
Picard Medical, Inc. (NYSE American: PMI) is the target of several securities fraud class-action lawsuits filed on behalf of investors. The legal actions, brought by firms including The Schall Law Firm and Rosen Law Firm, cover investments made between September 2, 2025, and October 31, 2025. The lawsuits allege that during this period, Picard Medical violated sections of the Securities Exchange Act of 1934 by making materially false and misleading statements. Investors seeking to serve as lead plaintiff in the litigation have a deadline of April 3, 2026.
Lawsuit Alleges Misinformation Fueled Coordinated Share Dumping
The core of the allegations centers on a fraudulent stock promotion scheme. According to the lawsuits, the company's stock price was artificially inflated through social media-based misinformation, which included the impersonation of financial professionals. The filings claim that during this price inflation campaign, company insiders and their affiliates used offshore or nominee accounts to facilitate a coordinated sell-off of their shares. The suits argue that Picard’s public statements and risk disclosures failed to mention the artificial trading activity, thereby misleading investors about the company's business and prospects.
Company Promotes Artificial Heart as Legal Challenges Mount
As these legal challenges emerge, Picard Medical is simultaneously promoting its core technology. On March 13, 2026, the company announced its subsidiary's SynCardia Total Artificial Heart (STAH) would be featured on a BTV Business Television program. The company highlighted that its device, the first FDA-approved total artificial heart, has been implanted in over 2,100 patients worldwide. This promotional effort presents a stark contrast to the serious allegations regarding its stock trading practices from late 2025, creating significant reputational and financial uncertainty for the medical device maker.
